An Open-label Study to Evaluate the Safety and Effect on Disease Progression and Overall Survival of Avastin Plus Taxane-based Chemotherapy in Patients With Locally Recurrent or Metastatic Breast Cancer
An Open-label Study to Evaluate the Safety and Effect on Disease Progression and Overall Survival of Avastin Plus Taxane-based Chemotherapy in Patients With Locally Recurrent or Metastatic Breast Cancer
This single arm study will assess the safety and efficacy of a regimen of Avastin plus a taxane, with or without additional chemotherapy, as first-line treatment in patients with locally recurrent or metastatic breast cancer. All patients will receive Avastin (10mg/kg iv every 2 weeks, or 15 mg/kg iv every 3 weeks) plus taxane-based chemotherapy. If taxanes are contraindicated, alternative chemotherapy (other than anthracyclines or pegylated liposomal doxorubicin) may be used. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.
Inclusion Criteria:
Exclusion Criteria:
Ried-innkreis, 4910, Austria
Saint-denis de La Reunion, 97400, France
Ac Amsterdam, 1091, Netherlands
Capelle Ad Yssel, 2906 ZC, Netherlands
Delftzijl, 9934 JD, Netherlands
Navarra, 31008, Spain
Sabadell, Barcelona, 08208, Spain
Westcliffe-on-sea, SS0 0RY, United Kingdom